Literature DB >> 24799748

Statin-induced rhabdomyolysis: a comprehensive review of case reports.

Polyana Mendes1, Priscila Games Robles1, Sunita Mathur2.   

Abstract

PURPOSE: To identify case reports of statin-induced rhabdomyolysis and summarize common predisposing factors, symptoms, diagnostic findings, functional outcomes, characteristics, treatment, and rehabilitation.
METHOD: MEDLINE, CINAHL, SCOPUS, and PEDro databases were searched (1990-2013) for relevant case reports using the search terms "Statins," "Rhabdomyolysis," "Myalgia," "Muscle damage," "Muscle injury," and "Myopathy." Relevance (based on title and abstract) was assessed by one investigator; two investigators independently reviewed the relevant articles to determine inclusion in the review.
RESULTS: A total of 112 cases met the inclusion criteria. The majority were in men (70%) and people over 45 years of age (mean 64 [SD 14] years). Simvastatin was the most commonly reported statin (n=55); the majority of cases reported the use of concomitant medications such as fibrates (n=25). Weakness (n=65) and muscle pain (n=64) were the most common symptoms. In 19 cases, the patient was referred to rehabilitation, but the case reports do not include descriptions of the treatment.
CONCLUSION: Statin-induced rhabdomyolysis was more commonly reported when statins were used in conjunction with other drugs, which potentiated its effect. Research is needed to identify the role of exercise and rehabilitation following statin-induced rhabdomyoloysis since muscle damage may be severe and may have long-term effects on muscle function.

Entities:  

Keywords:  HMG-CoA; muscular diseases; rhabdomyolysis; statins

Year:  2014        PMID: 24799748      PMCID: PMC4006404          DOI: 10.3138/ptc.2012-65

Source DB:  PubMed          Journal:  Physiother Can        ISSN: 0300-0508            Impact factor:   1.037


  28 in total

1.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

Review 2.  Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Authors:  Stefano Bellosta; Rodolfo Paoletti; Alberto Corsini
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

3.  Statin safety: an appraisal from the adverse event reporting system.

Authors:  Michael H Davidson; John A Clark; Lucas M Glass; Anju Kanumalla
Journal:  Am J Cardiol       Date:  2006-02-03       Impact factor: 2.778

Review 4.  Effects of statins on skeletal muscle: a perspective for physical therapists.

Authors:  Stephanie L Di Stasi; Toran D MacLeod; Joshua D Winters; Stuart A Binder-Macleod
Journal:  Phys Ther       Date:  2010-08-05

5.  Magnitude of spinal muscle damage is not statistically associated with exercise-induced low back pain intensity.

Authors:  Mark D Bishop; Maggie E Horn; Donovan J Lott; Ishu Arpan; Steven Z George
Journal:  Spine J       Date:  2011-12       Impact factor: 4.166

6.  Distribution of serum creatine kinase activity in young healthy persons.

Authors:  E I Lev; I Tur-Kaspa; I Ashkenazy; A Reiner; D Faraggi; J Shemer; Z Argov
Journal:  Clin Chim Acta       Date:  1999-01       Impact factor: 3.786

Review 7.  Clinical perspectives of statin-induced rhabdomyolysis.

Authors:  Kenneth A Antons; Craig D Williams; Steven K Baker; Paul S Phillips
Journal:  Am J Med       Date:  2006-05       Impact factor: 4.965

Review 8.  The controversies of statin therapy: weighing the evidence.

Authors:  J Wouter Jukema; Christopher P Cannon; Anton J M de Craen; Rudi G J Westendorp; Stella Trompet
Journal:  J Am Coll Cardiol       Date:  2012-08-15       Impact factor: 24.094

Review 9.  Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes.

Authors:  Beth A Parker; Paul D Thompson
Journal:  Exerc Sport Sci Rev       Date:  2012-10       Impact factor: 6.230

Review 10.  Safety considerations with fibrate therapy.

Authors:  Michael H Davidson; Annemarie Armani; James M McKenney; Terry A Jacobson
Journal:  Am J Cardiol       Date:  2006-12-08       Impact factor: 2.778

View more
  26 in total

1.  [Weakness of the extremities in a 73-year-old male patient].

Authors:  M Attaran-Bandarabadi; P Kalbasi Anaraki; W Gwinner; H Haller
Journal:  Internist (Berl)       Date:  2016-08       Impact factor: 0.743

2.  Rhabdomyolysis: a rare complication of Hashimoto's thyroiditis precipitated by statin therapy.

Authors:  Jayameena Peringat; Robin George Manappallil; Ummer Karadan
Journal:  BMJ Case Rep       Date:  2018-02-12

3.  Bone scintigraphy of severe hypercalcemia following simvastatin induced rhabdomyolysis.

Authors:  Zubair B Mirza; Sophia Hu; Louis F Amorosa
Journal:  Clin Cases Miner Bone Metab       Date:  2017-02-10

4.  Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease.

Authors:  Yawen Jiang; Weiyi Ni
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

5.  Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis.

Authors:  Fraser Charles Goldie; Amy Brogan; James Graham Boyle
Journal:  BMJ Case Rep       Date:  2016-07-28

6.  Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.

Authors:  Jamie L Fleet; Eric McArthur; Aakil Patel; Matthew A Weir; Manuel Montero-Odasso; Amit X Garg
Journal:  CMAJ       Date:  2019-09-16       Impact factor: 8.262

7.  Optimal duration for continuation of statin therapy in bacteremic patients.

Authors:  Ajinkya M Pawar; Kerry L LaPlante; Tristan T Timbrook; Aisling R Caffrey
Journal:  Ther Adv Infect Dis       Date:  2018-05-17

Review 8.  The Value of Lactate Dehydrogenase in Predicting Rhabdomyolysis-Induced Acute Renal Failure; a Narrative Review.

Authors:  Hazhir Heidari Beigvand; Kamran Heidari; Behrooz Hashemi; Amin Saberinia
Journal:  Arch Acad Emerg Med       Date:  2021-03-09

9.  An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase.

Authors:  George Chapman; Stephanie Tanner
Journal:  BMJ Case Rep       Date:  2020-02-10

10.  Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4.

Authors:  Meng Meng; Xin Li; Xiuwen Zhang; Bin Sun
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.